Literature DB >> 24556061

High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.

Ellen Stelloo1, Remi A Nout2, Lisanne C L M Naves1, Natalja T Ter Haar1, Carien L Creutzberg2, Vincent T H B M Smit1, Tjalling Bosse3.   

Abstract

OBJECTIVE: Molecular alterations in endometrial cancer have been shown to be prognostically significant but have not yet been implemented in the current clinical risk assessment. Few studies have investigated the reliability of molecular alterations in pre-operative specimens. Therefore, the objective was to determine whether molecular analysis of pre-operative endometrial cancer samples accurately reflects those alterations in the subsequent hysterectomy specimens.
METHODS: Paired pre-operative and hysterectomy specimens of 48 patients diagnosed with endometrial carcinoma, 42 endometrioid (EEC) and 6 non-endometrioid (NEEC) carcinomas, were analyzed for immunohistochemical expression of p53, PTEN and β-catenin. Tumor DNA was isolated and analyzed for microsatellite instability (MSI), TP53 mutations and somatic hot spot mutations in 13 genes.
RESULTS: In EEC patients, loss of PTEN, nuclear β-catenin and p53-mutant expression was found in 43%, 7% and 12%, respectively. No nuclear β-catenin was found in 5 of 6 NEEC patients, all serous cancers, whereas a p53-mutant expression was present in all serous cases. MSI was found in 19.5%, all EEC. Concordance for PTEN, β-catenin, p53 expression and MSI status was found in 79%, 92%, 79% and 93.5%, respectively. We detected 65 hot spot mutations in 39/48 (81%) tumors. Overall concordance of the GynCarta multigene analysis was 99.8%.
CONCLUSIONS: The results confirm the reliability of immunohistochemical and DNA-based techniques in the evaluation of molecular alterations in pre-operative endometrial specimens and high concordance rates with the definitive hysterectomy specimens. The resulting molecular signature provides initial pre-operative diagnostic information on the status of oncogenic pathways, which may contribute to individualized treatment strategies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Concordance; Curettage; Endometrial cancer; Hysterectomy; Microsatellite instability; Molecular alterations

Mesh:

Substances:

Year:  2014        PMID: 24556061     DOI: 10.1016/j.ygyno.2014.02.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Authors:  Alba Mota; Eva Colás; Pablo García-Sanz; Irene Campoy; Alejandro Rojo-Sebastián; Sonia Gatius; Ángel García; Luis Chiva; Sonsoles Alonso; Antonio Gil-Moreno; Xavier González-Tallada; Berta Díaz-Feijoo; August Vidal; Patrycja Ziober-Malinowska; Marcin Bobiński; Rafael López-López; Miguel Abal; Jaume Reventós; Xavier Matias-Guiu; Gema Moreno-Bueno
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

2.  Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.

Authors:  Jennifer G Haag; Rebecca J Wolsky; Marisa R Moroney; Jamie Sheren; Jeanelle Sheeder; Benjamin G Bitler; Bradley R Corr
Journal:  Int J Gynecol Pathol       Date:  2022-03-14       Impact factor: 3.326

3.  Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.

Authors:  Donghai Dai; Kristina W Thiel; Erin A Salinas; Michael J Goodheart; Kimberly K Leslie; Jesus Gonzalez Bosquet
Journal:  Gynecol Oncol       Date:  2016-05-16       Impact factor: 5.482

4.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Authors:  Aline Talhouk; Lien N Hoang; Melissa K McConechy; Quentin Nakonechny; Joyce Leo; Angela Cheng; Samuel Leung; Winnie Yang; Amy Lum; Martin Köbel; Cheng-Han Lee; Robert A Soslow; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Gynecol Oncol       Date:  2016-07-14       Impact factor: 5.482

5.  Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues.

Authors:  Xiaoping Ma; Yuzuo Hui; Li Lin; Yu Wu; Xian Zhang; Peishu Liu
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

6.  A clinically applicable molecular-based classification for endometrial cancers.

Authors:  A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

Review 7.  New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Authors:  A Talhouk; J N McAlpine
Journal:  Gynecol Oncol Res Pract       Date:  2016-12-13

8.  Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

Authors:  Manouk van Esterik; Inge C Van Gool; Cor D de Kroon; Remi A Nout; Carien L Creutzberg; Vincent T H B M Smit; Tjalling Bosse; Ellen Stelloo
Journal:  Oncotarget       Date:  2017-04-11

Review 9.  Clinical actionability of molecular targets in endometrial cancer.

Authors:  Mary Ellen Urick; Daphne W Bell
Journal:  Nat Rev Cancer       Date:  2019-08-06       Impact factor: 60.716

10.  Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Authors:  Ellen Stelloo; Tjalling Bosse; Remi A Nout; Helen J MacKay; David N Church; Hans W Nijman; Alexandra Leary; Richard J Edmondson; Melanie E Powell; Emma J Crosbie; Henry C Kitchener; Linda Mileshkin; Pamela M Pollock; Vincent T Smit; Carien L Creutzberg
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.